{"id":177869,"date":"2025-10-19T01:13:21","date_gmt":"2025-10-19T01:13:21","guid":{"rendered":"https:\/\/teknomers.com\/en\/recent-advancements-in-early-stage-breast-cancer-new-therapies-will-raise-survival-rates-above-90-in-the-next-ten-years\/"},"modified":"2025-10-19T01:13:21","modified_gmt":"2025-10-19T01:13:21","slug":"recent-advancements-in-early-stage-breast-cancer-new-therapies-will-raise-survival-rates-above-90-in-the-next-ten-years","status":"publish","type":"post","link":"https:\/\/teknomers.com\/en\/recent-advancements-in-early-stage-breast-cancer-new-therapies-will-raise-survival-rates-above-90-in-the-next-ten-years\/","title":{"rendered":"Recent advancements in early-stage breast cancer: “New therapies will raise survival rates above 90% in the next ten years.”"},"content":{"rendered":"\n
\n
\n
\n
\n
\n
\n\"Pilar
\n<\/source><\/source>\n<\/picture>\n<\/div>\n<\/figure>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n
\n

Actualizado <\/span>

\n

The Rise of Breast Cancer Awareness and Treatment Options<\/h2>\n

Breast cancer remains one of the most prevalent<\/strong> cancers affecting women worldwide, with estimates suggesting that one in eight women<\/strong> will face this diagnosis in their lifetime. Following the initial shock of a diagnosis, many patients find solace in the support network<\/strong> and the expanding array of therapeutic options<\/strong> available. Joaqu\u00edn Gavil\u00e1, a prominent figure in oncology and a board member of Solti, emphasizes that “the options are growing increasingly diverse.”<\/p>\n

This year, vital medical advancements coincide with significant dates that underscore the global fight against breast cancer. Antonio Llombart, head of Medical Oncology at the Hospital Arnau de Vilanova in Valencia, celebrates these novel treatments that could lead us to a 90% survival rate<\/strong> over the next decade. \u201cThe vast array of studies demonstrates that effective options are emerging, especially in breast cancer, unlike in other malignancies,\u201d he expressed, lamenting the fewer options available for severe cancers like pancreatic cancer.<\/p>\n

Promising Results from Recent Clinical Trials<\/h2>\n

The latest clinical trial results reveal a positive trajectory: longer survival rates among patients diagnosed at early stages, with minimal toxicities reported. According to Llombart, these treatments are poised to make their clinical debut once they navigate regulatory hurdles. One notable advancement focuses on therapies enhancing survival rates for the luminal HR-positive and HER2-negative subtype, which accounts for nearly 70% of breast cancer diagnoses.<\/strong> In Spain alone, this represents approximately 26,370 women<\/strong>, as the annual estimate stands around 37,682 new cases<\/strong> of breast cancer.<\/p>\n

A significant player in this evolution is abemaciclib<\/strong>, a drug developed in Spain. Women like Concepci\u00f3n D\u00edaz, who was diagnosed in 2020, have found hope through its use. “After surgeries, my oncologist encouraged me to participate in a trial alongside other patients, where I took this medication for two years,” recalls D\u00edaz. “It’s been nearly three years since my last dose, and I have not relapsed,” she adds, reflecting on the impact of her successful therapy.<\/p>\n

The MonarchyE trial<\/strong> showcases a remarkable 15.8% reduction<\/strong> in the risk of death seven years post-treatment initiation. Gavil\u00e1 describes these findings as groundbreaking, especially given that over 30% of these patients<\/strong> experience a relapse within five years and up to 40%<\/strong> during the next decade. “Ultimately, we seek global survival\u2014avoiding dreaded relapses, which limit treatment options due to resistance,” he stresses.<\/p>\n

Alternative Treatment Options for Breast Cancer<\/h2>\n

For patients who may not be eligible for abemaciclib, another viable option is ribociclib.<\/strong> This promising drug has demonstrated significant advantages against hormone-sensitive breast tumors. Manuel Borrego, an investigator involved in the high-recruitment Natalee trial<\/strong> in Europe, highlights that ribociclib has proven effective in reducing relapse rates for this patient demographic.<\/p>\n

In addition, HER2-positive breast cancers, known for their aggressive nature and representing about 15% of cases<\/strong>, are set to benefit from early intervention. Findings from the Destiny Breast11 trial<\/strong> reveal that administering the antibody-drug conjugate trastuzumab deruxtecan<\/strong> prior to surgical intervention significantly enhances complete treatment responses compared to standard chemotherapy protocols.<\/p>\n

Santiago Escriv\u00e1 de Roman\u00ed, a medical oncologist at Vall d’Hebron University Hospital who participated in this study, underscores the importance of effectively eliminating viable cells at the time of surgery to preempt relapses. Rodrigo S\u00e1nchez Bayona of the Spanish Society of Medical Oncology (SEOM) reinforces that these studies reflect a critical evolution towards smarter, more targeted<\/strong>, and personalized treatment strategies.<\/strong><\/p>\n

In conclusion, the landscape of breast cancer treatment is advancing rapidly, characterized by innovative therapies and improved outcomes for patients. With ongoing research and clinical trials, there is renewed hope in achieving higher survival rates and reducing recurrence in breast cancer, thus transforming the lives of countless women affected by this disease. The collaboration of medical professionals, researchers, and patients will continue to shape the future of oncology, fostering a promising path forward.<\/p>\n


\n
General News – 2<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Actualizado Domingo, 19 octubre 2025 – 02:37 The Rise of Breast Cancer Awareness and Treatment Options Breast cancer remains one of the most prevalent cancers affecting women worldwide, with estimates suggesting that one in eight women will face this diagnosis in their lifetime. Following the initial shock of a diagnosis, many patients find solace in […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[36400],"tags":[1591,36717,36729,26681],"class_list":["post-177869","post","type-post","status-publish","format-standard","hentry","category-health","tag-cancer","tag-ciencia-y-salud","tag-ciencia-y-salud-salud","tag-salud"],"_links":{"self":[{"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/posts\/177869","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/comments?post=177869"}],"version-history":[{"count":0,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/posts\/177869\/revisions"}],"wp:attachment":[{"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/media?parent=177869"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/categories?post=177869"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/tags?post=177869"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}